PRIN settore LS1 codice 2020LW7XWH "Early Phase Preclinical Development of PACECOR, a Mutation-Independent Anti-SARS-Co2 Therapeutic Strategy" (DFM.AD004.324)
Area tematica
Scienze fisiche e tecnologie della materia
Area progettuale
Sistemi e materiali complessi, materia soffice, biofisica e reti (DFM.AD004)Struttura responsabile del progetto di ricerca
Responsabile di progetto
GIORGIA BRANCOLINI
Telefono: 0592055311
E-mail: giorgia.brancolini@cnr.it
Abstract
The proposed project is an integrated effort towards the prevention of infective spread of the SARS-CoV-2 virus and related viruses. To approach such challenge, the study will exploit the amalgamation of transversal competences, spanning from physical chemistry and bioinformatics to biomedicine, such as to warrant the operational multidisciplinary nature of the endeavours needed to take upon the various phases of the research programme. It is axiomatic that virus entrance into target cells is a key step to abrogate for halting infection, preventing the subsequent viremia in the host and viral dissemination. Current approaches in this direction have been biased towards targeting the virus, most conveniently
through the generation of specific immunological tools. However, an alternative approach could be todevise tolerable and highly selective pharmacological probes aimed at obstructing ancillary components of the virus-host interaction, whille desensitising the impact of genotypic changes of the virus.
Obiettivi
The proposed project is an integrated effort towards the prevention of infective spread of the SARS-CoV-2 virus and related viruses. To approach such challenge, the study will exploit the amalgamation of transversal competences, spanning from physical chemistry and bioinformatics to biomedicine, such as to warrant the operational multidisciplinary nature of the endeavours needed to take upon the various phases of the research programme. It is axiomatic that virus entrance into target cells is a key step to abrogate for halting infection, preventing the subsequent viremia in the host and viral dissemination. Current approaches in this direction have been biased towards targeting the virus, most conveniently
through the generation of specific immunological tools. However, an alternative approach could be todevise tolerable and highly selective pharmacological probes aimed at obstructing ancillary components of the virus-host interaction, whille desensitising the impact of genotypic changes of the virus.
Data inizio attività
25/04/2022
Parole chiave
pacecor, strategia terapeutica, anti-SARS-Co2
Ultimo aggiornamento: 14/12/2024